Anavex Life Sciences Q2 2024 GAAP EPS $(0.13) Misses $(0.11) Estimate, Cash and Equivalents of $139.4M
Anavex Life Sciences Q2 2024 GAAP EPS $(0.13) Misses $(0.11) Estimate, Cash and Equivalents of $139.4M
Anavex Life Sciences 2024年第二季度GAAP每股收益（0.13）未达到预期（0.11）美元，现金及等价物为1.394亿美元
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 176.47 percent decrease over earnings of $0.17 per share from the same period last year.
Anavex Life Sciences（纳斯达克股票代码：AVXL）公布的季度亏损为每股0.13美元，比分析师普遍预期的0.11美元（0.11美元）低18.18％。与去年同期的每股收益0.17美元相比，下降了176.47％。